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Salivary cytokine panel
indicative of non-small
cell lung cancer
Tomonobu Koizumi1, Vivek Shetty2 and
Masaki Yamaguchi3
Abstract
Objective: To develop a combinatorial panel of salivary cytokines that manifests the presence of
non-small cell lung cancer (NSCLC) that will eventually improve prognosis by facilitating the early
diagnosis and management of this common cancer.
Methods: We performed a case-control study comparing salivary cytokine profiles of 35 adult
subjects with NSCLC with those of 35 matched, healthy nonsmokers. Multiplex bead array assays
were used to quantify 27 cytokines in saliva, serum, and oral mucosal transudate samples. Logistic
regression analysis was used to develop an informative cytokine panel. Receiver operating char-
acteristic (ROC) curves were generated to evaluate the discriminant ability of the panel.
Results: A combinatorial 12-cytokine panel (interleukin receptor antagonist [IL1RN], IL1B, IL6,
IL7, IL8, IL10, C-C motif chemokine ligand 11 [CCL11], tumor necrosis factor, C-X-C motif
chemokine ligand 10 [CXCL10], C-C motif chemokine ligand 3, C-C motif chemokine ligand 4,
and platelet-derived growth factor-BB) distinguished patients with NSCLC from healthy controls.
Further, ROC analysis revealed that a cytokine panel comprising IL10 (odds ratio, 1.156) and
CXCL10 (odds ratio, 1.000) discriminated NSCLC with a sensitivity of 60.6% and specificity of
80.8% (area under the ROC curve, 0.701).
Conclusion: A combinatorial panel of select salivary cytokines indicates the presence
of NSCLC.
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Introduction
Lung cancer is one of the most common
malignancies worldwide, with considerable
associated morbidity and mortality.1 In
many countries, including Japan, lung
cancer is the leading cause of cancer-
related mortality.2 The majority (85%) of
these malignancies are classified as non-
small cell lung cancer (NSCLC). Surgery,
with other adjunctive treatment, is the pre-
ferred therapeutic option for patients with
early stages of NSCLC (5-year survival rate
approximately 70% to 80%).3 Yet, more
than half of patients with NSCLC initially
present with more advanced stages of the
disease. Although newer therapeutic strate-
gies such as molecular targeted agents have
marginally improved survival rates, the
prognosis of advanced-stage NSCLC is
stubbornly poor, with an overall 5-year
survival rate of 17%.4 Given that early
detection of NSCLC greatly increases
5-year survival rates, screening and identifi-
cation of NSCLC during its earliest stages
has been a major interest of the oncolo-
gy community.
Among the pathways to tumor forma-
tion and progression, the inflammatory
pathway has stimulated particular interest.5
Considerable evidence indicates that
inflammation may be an ancillary, or even
inseparable, aspect of tumor develop-
ment.6–10 Chronic inflammatory states asso-
ciated with infection and irritation may lead
to environments that promote genomic
lesions and the development of dysplasia.11
In particular, cytokines are secreted by
tumor and stromal cells in the tumor micro-
environment, and these factors can function
in an autocrine or paracrine manner
(or both) to perpetuate the tumor and facil-
itate local invasion and metastasis.12
The putative association of cytokines
with tumor development and progression
has led to interest in exploiting cytokines
as biological indicators of the presence or
progression of malignancies. Although
most attention focuses on developing dis-
tinct serum cytokine profiles of malignan-
cies, interest has increasingly pivoted to
the use of saliva as a diagnostic medium.
Saliva has several compelling attributes as
a biofluid for investigating systemic dis-
eases.13 Although the oral mucosal transu-
date (OMT) is not regularly used in the field
of oral health, its use will increase when
commercial collecting devices are intro-
duced. Saliva can be easily, repeatedly,
and noninvasively obtained and stored
without the use of specialized equipment.
Saliva poses a much smaller risk of expos-
ing clinicians and laboratory technicians to
pathogens such as human immunodeficien-
cy virus or hepatitis viruses.14
Numerous salivary analytes of interest in
biobehavioral research are constituents of
serum that are synthesized, stored, and
released from the granules within the secre-
tory cells of the saliva glands. Others con-
tribute to humoral immunity, such as
antibodies or cytokines secreted by neutro-
phils, macrophages, or lymphocytes in the
oral mucosa.15 Multiple molecules isolated
from saliva have been used as screening and
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diagnostic tools or as prognostic bio-
markers of diseases, including cancer.16–18
However, the role of cytokines in saliva as
a distant manifestation of lung malignan-
cies has been largely unexplored.
The primary aim of the present study
was to evaluate the association between sal-
ivary cytokine levels and the presence of
NSCLC. We hypothesized that the levels
of salivary cytokines in patients with
NSCLC vary with the severity of disease.
Moreover, combinatorial assessment of
cytokine levels may prove useful for screen-
ing for NSCLC. For this purpose, we char-
acterized cytokine profiles of the saliva of
patients with NSCLC and compared them
with those of normal, healthy matched sub-
jects. We further explored the relationships
between cytokine levels in saliva, serum,
and OMT in patients with NSCLC with
those of their matched controls.
Materials and methods
Subjects
The Ethics Committee of Shinshu
University and Shinshu University
Hospital approved this study. Written
informed consent was obtained from all
patients. Between March 2016 and July
2017, 35 adult patients (13 men and 22
women, aged 42 to 80 years; mean, 67.5
years, median 69.0 years) with Stages I–IV
NSCLC were recruited from the Shinshu
Cancer Center and the Department of
Thoracic Surgery of Shinshu University
Hospital. Diagnosis and staging of
NSCLC was confirmed by cytology and his-
topathology according to the WHO criteria.
Stages I, II, III, and IV tumors were defined
according to the Union for International
Cancer Control’s TNM staging criteria for
lung cancer (Ver. 7). Twenty-one (60%)
patients were stage I (IA and IB), two
(6%) were stage IIA, two (6%) were stage
IIIB, and 10 (28%) were stage IV.
Biological samples of patients with
NSCLC were obtained before pretreatment
such as chemotherapy or surgery. We
recruited 35 normal, healthy nonsmokers
who were not taking medication (17 men
and 18 women, aged 42 to 69 years; mean,
53.6 years; median, 52.0 years) to serve as
controls. An independent investigator,
unaware of the subjects’ laboratory data,
selected controls from a pool of hospital
staff and patients who were matched for
age, sex, and smoking habits to the
NSCLC patients.
Sample collection
Immunological data were acquired using
saliva, blood, and OMT. To assess diurnal
variations, saliva samples were collected
from patients three-times daily as follows:
morning (6:00–9:00), noon (11:00–13:00),
and evening (15:00–16:00). Saliva, blood,
and OMT samples were collected from all
subjects once daily at noon. Biological sam-
ples were collected before treatment. It is
possible that chronic periodontitis influen-
ces the concentrations of inflammatory and
anti-inflammatory cytokines.19 Therefore,
before procuring a biospecimen, any active
periodontal disease was excluded using a
test paper-strip method that detects occult
blood in saliva (Perioscreen; Sunstar Inc.,
Osaka, Japan). Subjects did not drink or
chew gum in the 30 minutes before saliva
collection. Commonly used cotton-based
absorbent materials can alter quantitative
estimates of the salivary analytes through
nonspecific binding, cross-linking, or filter-
ing constituent biomolecules.20,21 The saliva
samples were provided by the participants
using the passive-drool method, in which
participants allow saliva to pool in the
mouth and then drool it into a tube (MS-
50, Japan Medical Ltd., Tokyo, Japan).
Approximately 150 mL of whole saliva was
collected during 1 minute. Next, 4.5 mL of
whole blood was collected by a nurse using
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a vacuum blood collection tube (anticoagu-
lant, 3.2% sodium citrate; Terumo Co.,
Tokyo, Japan) from each participant.22,23
OMT samples were collected by the partic-
ipants for 5 minutes using an OraSure col-
lection device (OraSure Technologies, Inc.,
Bethlehem, PA, USA).24,25 The saliva,
blood, and OMT samples were stored
at 80C.
Clinical information and the results from
testing the samples were collected and
entered into a database by research staff
not directly involved in diagnosis, treat-
ment, or sample analysis. Patients’ diagnos-
tic and pathological data were masked
during sample collection and biomark-
er detection.
Multiplex analysis of cytokines
We used a multiplex bead array assay (Cat.
#M500KCAF0Y, Bi-Plex Pro Human
Cytokine Grp I Panel 27-Plex; Bio-Rad
Laboratories, Inc., Tokyo, Japan) that has
been used to measure salivary cyto-
kines.26,27 The cytokines were as follows:
interleukin (IL) receptor antagonist (RN);
IL1b; IL2; IL4; IL5; IL6; IL7; IL8; IL9;
IL10; IL12 (p70); IL13; IL15; IL17A; C-C
motif chemokine ligand 11 (CCL11); fibro-
blast growth factor 2 (FGF2); colony stim-
ulating factor 3 (CSF3); colony stimulating
factor 2 (CSF2); interferon gamma (IFN-c);
tumor necrosis factor (TNF); C-X-C motif
chemokine ligand 10 (CXCL10); C-C motif
chemokine ligand 2 (CCL2); C-C motif che-
mokine ligand (CCL3); C-C motif chemo-
kine ligand 4 (CCL4); platelet-derived
growth factor-BB (PDGF-BB); regulated
on activation, normal T cell expressed and
secreted (RANTES); and vascular endothe-
lial growth factor (VEGF). All were ana-
lyzed according to the manufacturer’s
instructions. The Bio-Plex Multiplex
Immunoassay employed human cytokine
panels, and the plates were read using a
Bio-Plex Array Reader (Bio-Plex 200
System and Bio-Plex Manager Version
6.1, Bio-Rad Laboratories, Inc.).
Saliva, blood, and OMT were prepared
using the same pretreatment. The biofluids
were frozen at 80C, thawed at 4C in a
refrigerator, equilibrated to room tempera-
ture (24C), and then added to the assay
plates. The samples were then centrifuged
at 1,500 g for 15 minutes, and a micropi-
pette was used to sample a 50-mL aliquot of
each sample for subsequent analysis.
Statistical analysis
Statistical analyses were performed using
IBM SPSS Statistics, version 25 (IBM
Corp., Armonk, NY, USA). Within-group
comparisons of diurnal variations in cyto-
kine levels were performed using one-
way analysis of variance (ANOVA).
Comparisons between two groups of cyto-
kine samples acquired at noon were evalu-
ated using the Mann–Whitney test. Unless
otherwise stated, data are expressed as the
mean standard deviation (SD), and
P< 0.05 indicates statistical significance.
Statistical analysis was not performed if
the number of data points missing from
one group was >18.
We used logistic regression analysis to
evaluate the association between the levels
of salivary cytokines and the presence of
NSCLC.28 The outcome variables for the
development of NSCLC were 0 for “no”
and 1 for “yes”. To generate a multivariable
logistic regression model, the results of
the Mann–Whitney test (P< 0.05) and the
backward elimination method were used.
The influence of a variable on the likelihood
of detecting NSCLC is expressed as the
odds ratio (OR), 95% confidence inter-
val (CI).
The performance of the model was
assessed using a discrimination test com-
bined with receiver operating characteristic
(ROC) analysis.29 ROC curves were gener-
ated to verify the discriminatory power of
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the salivary cytokine levels. The areas under
the curves (AUCs) were calculated to pro-
vide an overall summary of the diagnostic
accuracy of the comparisons of salivary
cytokine levels. Diagnostic performance
was classified as follows: poor, 0.50
AUC< 0.69; good, 0.70AUC< 0.89;
and excellent, 0.90  AUC< 1.
Results
Multiplex analysis of cytokines in biofluids
Table 1 summarizes the backgrounds of the
subjects and the number of samples. Of the
27 target cytokines, only 21 salivary cyto-
kines were detected in patients with NSCLC
because of insufficient sensitivity of the Bio-
Plex system for detecting IL2, IL4, IL15,
IL17A, FGF2, and CSF2. When the diur-
nal variations in the salivary cytokines of
the NSCLC patients were evaluated using
one-way ANOVA, significant differences
were observed for eight salivary cytokines
as follows: IL1RN, IL7, IL8, IL10, IL13,
CCL11, IFN-c, and TNF (P< 0.05). With
the exception of IL6, CSF3, CXCL10, and
CCL3, the levels of salivary cytokines in the
morning generally were the highest.
The correlation coefficients of biofluid
levels were calculated using data from the
patients with NSCLC and the controls. The
correlation coefficients of the serum vs
saliva levels ranged between 0.20
(PDGF-BB) and 0.55 (CCL11). For the
positive values, the maximum, minimum,
and mean were 0.55 (CCL11), 0.02 (IL8),
and 0.18, respectively. For the negative
values, the maximum, minimum, and
mean were 0.01 (VEGF), 0.20 (PDGF-
BB), and 0.09, respectively. The correla-
tion coefficients of the serum vs OMT levels
ranged between 0.18 (CCL2) and 0.26
(IL6). For the positive values, the maxi-
mum, minimum, and mean were 0.26
(IL6), 0.01 (VEGF), and 0.07, respectively.
For the negative values, the maximum, min-
imum, and mean were 0.01 (IL4), 0.18
(CCL2), and 0.09, respectively. The corre-
lation coefficients of saliva vs OMT levels
ranged between 0.13 (IL5) and 0.91
(CCL3). For the positive values, the maxi-
mum, minimum, and mean were 0.91
(CCL3), 0.19 (IL1RN), and 0.46, respec-
tively. For the negative values, the
maximum, minimum, and mean were
0.01 (IL17A), 0.13 (IL5), and 0.07,
respectively.
Table 2 shows the results of multiplex
analysis of cytokine levels in biofluids at
noon and the two-group comparisons
using the Mann–Whitney test (n¼ 35). For
statistical analysis, cytokine levels less than
the limit of detection are presented as half
the limit of detection.30,31 The levels of sal-
ivary cytokines of the patients with NSCLC
Table 1. Summary of subjects’ backgrounds and biofluid samples
Group
Male/Female Smoking status,
Sample number, n
(n¼ 35) n (%) Histology, n (%) Morning Noon Evening
NSCLC 13/22 Never 21 (60) Adenocarcinoma 32 (91) serum – 33 –
Former 14 (40) Squamous cell
carcinoma
3 (9) saliva 35 35 35
OMT – 35 –
Control 17/18 Never 27 (77) serum – 35 –
Former 8 (23) saliva – 35 –
OMT – 35 –
Abbreviation: non-small cell lung cancer (NSCLC).
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ranged between 0.01 (IL13) and 29,519.09
(IL1RN) pg/mL. In contrast, the cytokine
levels of the control subjects ranged
between 0.01 (IL4, IL6, IL13, and PDGF-
BB) and 9,257.21 (IL1RN) pg/mL. For the
noon samples, significant differences were
observed between the salivary cytokine
levels of the patients with NSCLC and con-
trols as follows: IL1RN, IL1B, IL7, IL10,
CCL11, TNF, CXCL10, and PDGF-BB
(P< 0.05) (Figure 1a). Significant differen-
ces in serum cytokine levels at noon
between patients with NSCLC and controls
were as follows: CCL11, CXCL10, and
CCL4 (P< 0.05) (Figure 1b). IL2 and
IL15 were undetectable. There were signifi-
cant differences in OMT cytokine levels at
noon between patients with NSCLC and
the controls as follows: IL1RN, IL4, IL6,
IL7, IL9, IL12 (p70), IL17A, CCL11,
FGF2, IFN-c, TNF, CXCL10, and CCL4
(P< 0.05) (Figure 1c). IL2, IL15, and CSF2
were undetectable.
To verify the possibility of screening for
NSCLC using the levels of salivary cyto-
kines, we used the data for morning,
noon, and evening of patients with
NSCLC (35 subjects 3 data points¼ 105).
Significant differences between the salivary
cytokine levels of patients and those of the
controls were as follows: IL1RN, IL1B,
IL6, IL7, IL8, IL10, CCL11, TNF,
CXCL10, CCL3, CCL4, and PDGF-BB
(P< 0.05) (Figure 1d).
Logistic regression analysis
The association between the salivary cyto-
kine levels of 12 cytokines and the risk of
NSCLC was evaluated using logistic regres-
sion analysis. The backward elimination
method identified the combination of sali-
vary cytokines IL10 and CXCL10 as the
most highly associated with NSCLC
(P< 0.05). In comparison, the P values
and ORs for all possible combinations of
analytes were calculated using a direct
(simultaneous) method. Cytokines signifi-
cantly associated (P< 0.05) with NSCLC
were present in three combinations when
two types of cytokines were used
Figure 1. Comparison of the salivary cytokine
levels between patients with non-small cell lung
cancer and controls (Mann–Whitney test)
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(Table 3). A significant association with
NSCLC was not observed when more
than three cytokines were used.
Ultimately, the combination of IL10 and
CXCL10 had the maximum ORs as (1.156
for IL10 [95% CI 1.048–1.275] and 1.000
for CXCL10 [95% CI 1.000–1.001]).
A multivariable prediction model (logis-
tic model) for the risk of NSCLC was built
using IL10 and CXCL10 as follows:
z ¼ 0:145 IL10þ 0:0003CXCL10 (1)
f zð Þ ¼ 1
1þ ez (2)
where z is an index that combines the crite-
ria variables, and f(z) is a logistic function.
ROC analysis
To confirm the preceding findings, we per-
formed ROC analysis. Figure 2 shows the
ROC of the presence of NSCLC when
IL10 and CXCL10 were used. The AUC
was 0.701 (P¼ 0.000, 95% CI 0.602–
0.801), which demonstrates “good” capabil-
ity for discriminating between patients with
NSCLC and controls. The optimal cutoff
values of sensitivity and specificity were
60.6% and 80.8%, respectively. The cutoff
values of the logistic function f(z) between
the true positives and false negatives ranged
from 0.698 to 0.708. The cutoff values for
the logistic function between the true nega-
tives and false positives ranged from 0.702 to
0.719. Thus, the cutoff values of the logistic
function ranged from 0.702 to 0.708.
For comparison, the ROCs of IL10 and
CXCL10 are shown in Figure 2. The values
of the AUC, sensitivity, and specificity of
IL10 were 0.660, 71.7, and 62.9, respective-
ly. The values of the AUC, sensitivity, and
specificity of CXCL10 were 0.622, 42.9, and
80.0, respectively. The maximum AUC was
achieved when the maximum values of IL10
and CXCL10 were combined.
Table 3. Outcomes of the logistic regression analysis of patients with NSCLC
Cytokines
Regression
coefficient, b
Standard
error P value Odds ratio
95% confidence
interval
IL10 0.145 0.050 0.004 1.156 1.048–1.275
CXCL10 0.000 0.000 0.021 1.000 1.000–1.001
IL1B 0.002 0.001 0.018 1.002 1.000–1.004
CXCL10 0.000 0.000 0.011 1.000 1.000–1.001
IL6 0.041 0.020 0.039 1.042 1.002–1.083
CXCL10 0.000 0.000 0.006 1.000 1.000–1.001
Abbreviations: non-small cell lung cancer (NSCLC); interleukin (IL); C-X-C motif chemokine ligand 10 (CXCL10).
Figure 2. Receiver operating characteristic
analysis of interleukin 10 and C-X-C motif
chemokine ligand 10 levels to determine the risk
of non-small cell lung cancer
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Discussion
The results of the present study support our
working hypothesis that differential levels
of certain salivary cytokines in patients
with NSCLC and combinatorial assessment
of cytokine levels are useful for screening
for NSCLC. Our findings are limited by
the inability to study age-matched, healthy
nonsmokers and subjects with a mean age
of 67.5 years to serve as our control group.
Even after controlling for diurnal variation,
the levels of IL1RN, IL7, IL8, IL10, IL13,
CCL11, IFN-c, and TNF were significantly
different. The cytokines were grouped as
inflammatory (IL7, IL8, CCL11, IFN-c,
and TNF) and anti-inflammatory (IL1RN,
IL10, and IL13) cytokines. The levels of sal-
ivary cytokines that varied with a circadian
rhythm in patients with NSCLC did not
depend on their functional category or con-
centrations in saliva. Typically, the levels of
anti-inflammatory cytokines that vary with
a circadian rhythm are higher shortly after
waking and lower before sleeping.32,33 In
the present study, the levels of all salivary
anti-inflammatory cytokines were higher in
the morning, consistent with previ-
ous findings.
Multivariable analysis of cytokine levels
in saliva, serum, and OMT revealed that
saliva and OMT had incremental beneficial
utility compared with serum. Salivary
cytokines are being assessed for their asso-
ciations with oral diseases such as periodon-
titis, gingivitis, cancer, and other systemic
diseases. For example, Khan detected
numerous cytokines and chemokines in
saliva samples of normal subjects.34
Compared with matched controls, the sam-
ples from patients with NSCLC studied
here showed significant differences in cyto-
kine levels in saliva (8 types), serum
(3 types), and OMT (13 types). There were
fewer significant differences in cytokine
levels in serum compared with saliva or
the OMT. In contrast, the cytokine levels
in saliva and the OMT were highly concor-
dant, judged by the correlation coefficients
of cytokine levels in serum and saliva com-
pared with those of serum and the OMT.
Saliva is a major component of the OMT,
and one can therefore surmise that the ease
of collection may serve as the major deter-
minant when choosing between the two bio-
fluids. Generally, the passive-drool method
for collecting saliva samples is quick and
simple compared with techniques for col-
lecting the OMT.
The combinatorial assessment of salivary
cytokine levels shows promise for screening
for the presence of NSCLC. The levels of
cytokines at all sampling times differed sig-
nificantly between patients with NSCLC
and controls as follows: IL1RN, IL1B,
IL6, IL7, IL8, IL10, TNF, CCL11,
CXCL10, CCL3, CCL4, and PDGF-BB
(P< 0.05) (Figure 1d). The levels of eight
of these salivary cytokines differed signifi-
cantly in the morning (Figure 1a).
However, the morning levels were not rep-
resentative of the differences between
patients with NSCLC and healthy controls.
ROC analysis supports the assertion that
NSCLC can be detected by measuring the
levels of salivary cytokines when using a
selective model employing IL10 and
CXCL10 (Figure 2).
Our present data provide preliminary
support for utilizing differential levels of
salivary IL10 and CXCL10 as indicators
of existing NSCLC. Emerging research sup-
ports our strategy that employed a panel of
inflammatory cytokines to detect NSCLC.
For example, Daly et al.35 measured the
expression levels of candidate biomarkers
of individuals at high-risk for lung cancer
and identified a panel of seven analytes,
mainly inflammatory cytokines such as
IL6, IL10, IL1RN, and TNF. DeCotiis
et al.36 measured inflammatory cytokines
in serum and concluded that cytokine bio-
markers may serve as a promising tool
for the detection of lung cancer.
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However, these two studies35,36 did not
identify CXCL10.
IL10 is an anti-inflammatory pleotropic
cytokine that is present in the exhaled
breath of patients with lung cancer.37 IL10
is produced by normal and neoplastic cells
and likely contributes to autoimmunity,
transplantation tolerance, and tumorigene-
sis.38 The levels of serum IL10 present in
patients with NSCLC are higher compared
with those of healthy control subjects.39 An
emerging body of research supports the
plausibility of our findings.35,36 Thus,
CXCL10 is a potent angiostatic cysteine-X
amino acid-cysteine (CXC) chemokine40
that regulates NSCLS-induced angiogene-
sis, tumor growth, and spontaneous metas-
tasis.41 The levels of CXCL10 detected in
surgical specimens of NSCLC tumors are
significantly higher compared with speci-
mens of adjacent normal lung tissue.42
These findings may explain why CXCL10
was identified using the Mann–Whitney
test when we included patients with stages
II–IV NSCLC (Figure 1d).
Despite its small sample size, our study
shows potential utility for measuring the
levels of salivary biomolecules that signifi-
cantly differ among patients with NSCLC
and controls. NSCLC comprises the adeno-
carcinoma, squamous cell carcinoma
(SCC), and large cell carcinoma subtypes.
The mechanisms of tumorigenesis and
molecular characteristics of SCC differ
from those of adenocarcinoma. The rela-
tionships of histological types and the
immune environment with the levels of
associated cytokines seem worthy of
future study. The discovery of a saliva-
based biomarker panel may represent a
significant source of discriminatory bio-
markers for detecting NSCLC. Equally
important, or study shows the translational
promise of the emerging field of salivary
diagnostics for systemic diseases. The ease
of saliva collection and continuing advances
in high-throughput technologies that allow
quick and incisive insights into saliva’s con-
stituents are advancing the use of oral fluids
as a credible diagnostic alternate to
other biofluids.
Our study shows the promise of utilizing
differential levels of salivary cytokines for
point-of-care testing, thus allowing
NSCLC to be detected to facilitate thera-
peutic intervention and improve survival
rates. The results of our study will likely
serve as a foundation for validation studies
that evaluate the temporal changes in sali-
vary cytokine levels and investigate their
associations with response to treatment,
relapse, complications, and survival. It is
conceivable that the levels of IL10 and
CXCL10 will return to normal after surgi-
cal treatment of NSCLC.
Conclusions
This study revealed significant differences in
the levels of certain salivary cytokines
between patients with NSCLC and control
groups. In particular, a 12-cytokine panel
(IL1RN, IL1B, IL6, IL7, IL8, IL10, TNF,
CCL11, CXCL10, CCL3, CCL4, and
PDGF-BB) distinguished patients with
NSCLC from healthy controls. ROC anal-
ysis revealed that a two-cytokine panel
(IL10 and CXCL10) indicated the
presence of NSCLC with high sensitivity
and specificity.
Acknowledgments
We thank the patients and healthy subjects for
their support and participation in this study. We
also thank the staff in the Department of
Thoracic Surgery, Shinshu University Hospital,
Mariko Miyagawa, and Nanae Mitsui for their
helpful support.
Declaration of conflicting interest
The authors declare that there is no conflict
of interest.
Koizumi et al. 3579
Funding
This work was supported in part by grants for
the Development of Medical and Welfare
Devices, Development Of Low-Cost, Rapid,
and Noninvasive Diagnostic Technology for
Cancer using Salivary Biomarkers, Fukushima,
Japan; and from the Japan Society for the
Promotion of Science, Visualization of
Cancer by Cytokine Coding Method and
Biosensor-Array with Microcapsules [grant
number 16H03166].
ORCID iD
Masaki Yamaguchi http://orcid.org/0000-
0003-4177-761X
References
1. Dubey S and Powell CA. Update in lung
cancer 2008. Am J Respir Crit Care Med
2009; 179: 860–868.
2. Matsuda T, Marugame T, Kamo KI, et al.
Cancer incidence and incidence rates in Japan
in 2005: based on data from 12 Population-
based Cancer Registries in the Monitoring of
Cancer Incidence in Japan (MCIJ) Project.
Jpn J Clin Oncol 2001; 41: 139–147.
3. Rami-Porta R, Ball D, Crowley J, et al. The
IASLC Lung Cancer Staging Project: pro-
posals for the revision of the T descriptors
in the forthcoming (seventh) edition of the
TNM classification for lung cancer. J Thorac
Oncol 2007; 2: 593–602.
4. Siegel R, Ma J, Zou Z, et al. Cancer statis-
tics, 2014. CA Cancer J Clin 2014; 64: 9–29.
5. Brenner DR, Scherer D, Muir K, et al.
A review of the application of inflammatory
biomarkers in epidemiologic cancer
research. Cancer Epidemiol Biomarkers
Prev 2014; 23: 1729–1751.
6. Ballaz S and Mulshine JL. The potential
contributions of chronic inflammation to
lung carcinogenesis. Clin Lung Cancer
2003; 5: 46–62.
7. Allavena P, Garlanda C, Borrello MG, et al.
Pathways connecting inflammation and
cancer. Curr Opin Genet Dev 2008; 18: 3–10.
8. Engels EA. Inflammation in the develop-
ment of lung cancer: epidemiological
evidence. Expert Rev Anticancer Ther 2008;
8: 605–615.
9. Mantovani A, Allavena P, Sica A, et al.
Cancer-related inflammation. Nature 2008;
454: 436–444.
10. Azad N, Rojanasakul Y and Vallyathan V.
Inflammation and lung cancer: roles of reac-
tive oxygen/nitrogen species. J Toxicol
Environ Health B Crit Rev 2008; 11: 1–15.
11. Tahara E. Growth factors and oncogenes
in human gastrointestinal carcinomas.
J Cancer Res Clin Oncol 1990; 116: 121–131.
12. Agnola CD and Biragyn A. Clinical utiliza-
tion of chemokines to combat cancer: the
double-edged sword. Expert Rev Vaccines
2007; 6: 267–283.
13. Wong DT. Salivary Diagnostics: Amazing
as it might seem, doctors can detect and
monitor diseases using molecules found in
a sample of spit. Am Sci 2008; 96: 37–43.
14. Yamaguchi M and Shetty V. Salivary
Sensors for Quantification of Stress
Response Biomarker. Electrochemistry
2011; 79: 442–446.
15. Granger DA, Johnson SB, Szanton SL, et al.
Incorporating salivary biomarkers into nurs-
ing research: an overview and review of best
practices. Biol Res Nurs 2012; 14: 347–356.
16. Byrne ML, O’Brien-Simpson NM, Reynolds
EC, et al. Acute phase protein and cytokine
levels in serum and saliva: a comparison of
detectable levels and correlations in a
depressed and healthy adolescent sample.
Brain Behav Immun 2013; 34: 164–175.
17. Kamatani T, Shiogama S, Yoshihama Y,
et al. Interleukin-1 beta in unstimulated
whole saliva is a potential biomarker for
oral squamous cell carcinoma. Cytokine
2013; 64: 497–502.
18. Rathnayake N, Akerman S, Klinge B, et al.
Salivary biomarkers for detection of system-
ic diseases. PLoS One 2013; 8: e61356.
19. Tomas I, Arias-Bujanda N, Alonso-
Sampedro M, et al. Cytokine-based predic-
tive models to estimate the probability of
chronic periodontitis: Development of diag-
nostic nomograms. Sci Rep 2017; 7: 11580.
20. Granger DA, Kivlighan KT, Fortunato C,
et al. Integration of salivary biomarkers into
developmental and behaviorally-oriented
research: problems and solutions for
3580 Journal of International Medical Research 46(9)
collecting specimens. Physiol Behav 2007;
92: 583–590.
21. Shirtcliff EA, Granger DA, Schwartz E,
et al. Use of salivary biomarkers in
biobehavioral research: cotton-based
sample collection methods can interfere
with salivary immunoassay results.
Psychoneuroendocrinol 2001; 26: 165–173.
22. Biancotto A, Feng X, Langweiler M, et al.
Effect of anticoagulants on multiplexed
measurement of cytokine/chemokines
in healthy subjects. Cytokine 2012;
60: 438–446.
23. Krishnan VV, Ravindran R, Wun T, et al.
Multiplexed measurements of immunomod-
ulator levels in peripheral blood of healthy
subjects: Effects of analytical variables based
on anticoagulants, age, and gender.
Cytometry B Clin Cytom 2014; 86: 426–435.
24. Fernandez-Botran R, Miller JJ, Burns VE,
et al. Correlations among inflammatory
markers in plasma, saliva and oral mucosal
transudate in post-menopausal women with
past intimate partner violence. Brain Behav
Immun 2011; 25: 314–321.
25. Chiang JJ, Eisenberger NI, Seeman TE,
et al. Negative and competitive social inter-
actions are related to heightened proinflam-
matory cytokine activity. Proc Natl Acad Sci
USA 2012; 109: 1878–1882.
26. Arellano-Garcia ME, Hu S, Wang J, et al.
Multiplexed immunobead-based assay for
detection of oral cancer protein biomarkers
in saliva. Oral Dis 2008; 14: 705–712.
27. Thorman R, Lundahl J, Yucel-Lindberg T,
et al. Inflammatory cytokines in saliva: early
signs of metabolic disorders in chronic
kidney disease. A controlled cross-sectional
study. Oral Surg Oral Med Oral Pathol Oral
Radiol Endod 2010; 110: 597–604.
28. Kleinbaum DG and Klein M. Logistic
regression. 3rd ed. New York: Springer
ScienceþBusiness Media LCC, 2010,
pp. 1–32.
29. DeLong ER, DeLong DM and Clarke-
Pearson DL. Comparing the areas under
two or more correlated receiver operating
characteristic curves: a nonparametric
approach. Biometrics 1988; 44: 837–845.
30. Kezic S, O’Regan GM, Lutter R, et al.
Filaggrin loss-of-function mutations are
associated with enhanced expression of
IL-1 cytokines in the stratum corneum of
patients with atopic dermatitis and in a
murine model of filaggrin deficiency.
J Allergy Clin Immunol 2012;
129: 1031–1039.
31. Attur M, Wang HY, Kraus VB, et al.
Radiographic severity of knee osteoarthritis
is conditional on interleukin 1 receptor
antagonist gene variations. Ann Rheum Dis
2010; 69: 856–861.
32. Agorastos A, Hauger RL, Barkauskas DA,
et al. Circadian rhythmicity, variability and
correlation of interleukin-6 levels in plasma
and cerebrospinal fluid of healthy men.
Psychoneuroendocrinol 2014; 44: 71–82.
33. Geiger SS, Fagundes CT, Siegel RM.
Chrono-immunology: progress and chal-
lenges in understanding links between
the circadian and immune systems.
Immunology 2015; 146: 349–358.
34. Khan A. Detection and quantitation of forty
eight cytokines, chemokines, growth factors
and nine acute phase proteins in healthy
human plasma, saliva and urine.
J Proteomics 2012, 75: 4802–4819.
35. Daly S, Rinewalt D, Fhied C, et al.
Development and validation of a plasma
biomarker panel for discerning clinical sig-
nificance of indeterminate pulmonary nod-
ules. J Thorac Oncol: IASLC 2013, 8: 31–36.
36. DeCotiis C, Hu Y, Greenberg AK, et al.
Inflammatory cytokines and non-small cell
lung cancer in a CT-scan screening cohort:
Background review of the literature. Cancer
Biomark 2016; 16: 219–233.
37. Kullmann T, Barta I, Csisze´r E, et al.
Differential cytokine pattern in the exhaled
breath of patients with lung cancer. Pathol
Oncol Res 2008; 14: 481–483.
38. Shih CM, Lee YL, Chiou HL, et al. The
involvement of genetic polymorphism of
IL-10 promoter in non-small cell lung
cancer. Lung Cancer 2005; 50: 291–297.
39. Arenberg DA, White ES, Burdick MD, et al.
Improved survival in tumor-bearing SCID
mice treated with interferon-c-inducible pro-
tein 10 (IP-10/CXCL10). Cancer Immunol
Immunother 2001; 50: 533–538.
40. De Vita F, Orditura M, Galizia G, et al.
Serum interleukin-10 levels as a prognostic
Koizumi et al. 3581
factor in advanced non-small cell lung
cancer patients. Chest 2000; 117: 365–373.
41. Arenberg DA, Kunkel SL, Polverini PJ,
et al. Interferon-y-inducible Protein 10
(IP-10) Is an Angiostatic Factor That
Inhibits Human Non-small Cell Lung
Cancer (NSCLC) Tumorigenesis and
Spontaneous Metastases. J Exp Med 1996;
184: 981–992.
42. Belperio JA, Keane MP, Arenberg DA, et al.
CXC chemokines in angiogenesis.
J Leukocyte Biol 2000; 68: 1–8.
3582 Journal of International Medical Research 46(9)
